All Posts

Summary:

Summary: The ACAD Trofinetide PDUFA is expected this Sunday March 12, 2023 Will we see an early decision before the weekend? See our full...

See this post for our current thoughts on ANAB. ANAB piqued our interest since 5 vs 0 hedge funds added them to their top 20 holdings in Q4 vs. Q3. However, the funds were probably looking for a stock jump on alopecia data in early Q1 2023, which unfortunately came back negative and hit the stock pretty hard, but it has rebounded to since the Jan 2023 readout (FIG. 1) FIG. 1 What are Amp's current thoughts and positions on ANAB? Overall, we are cautiously bullish on ANAB fro

First published 3/6/23 - currently in progress Summary: ESPR CLEAR outcomes data from NEXLETOL trial reported over the weekend at ACC.23...

Last week was a green week for XBI (biotech ETF), which finished the week up +2.3%, see the biggest news from last week, including a full...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: Several recent oncology investor conferences are still available to the public, including all company webcasts These conferences...

Summary

First posted 3/10/2023; last updated 5/1/2023 Summary: Many exciting rare diseases catalysts are coming throughout the year See the table...

SUMMARY